HTD1801,新型糖尿病薬 HTD1801, 2型糖尿病患者の腎機能が著しく低下し,腎機能が向上した. HTD1801, a new diabetes drug, significantly lowered blood sugar and improved kidney function in trial patients with type 2 diabetes.

HighTide TherapeuticsはEASDの会合で,SYMPHONY 2試験のフェーズ3の陽性な結果を発表し,そのクラスで初の抗炎症代謝調節剤であるHTD1801が,プラセボと比較して2型糖尿病患者のHbA1cレベルを有意に低下させたことを示した. HighTide Therapeutics announced positive Phase 3 results from the SYMPHONY 2 trial at the EASD meeting, showing HTD1801, a first-in-class anti-inflammatory metabolic modulator, significantly reduced HbA1c levels in type 2 diabetes patients compared to placebo. AMPKを活性化し,NLLLP3インパクトを抑制する療法は,グルコース制御,腎機能機能の改善,消化機能の改善,安全性に有利なプロファイルと重度低 血糖症をなくす. The therapy, which activates AMPK and inhibits the NLRP3 inflammasome, also improved glucose control, renal function, and inflammatory markers, with a favorable safety profile and no severe hypoglycemia. HTD1801は心臓血管疾患の総合的治療に役立つかもしれない. The findings suggest HTD1801 may serve as a comprehensive treatment for cardiovascular-kidney-metabolic disease.